Bioleaders Corporation (142760) - Total Assets
Based on the latest financial reports, Bioleaders Corporation (142760) holds total assets worth ₩42.61 Billion KRW (≈ $28.87 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 142760 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Bioleaders Corporation - Total Assets Trend (2015–2025)
This chart illustrates how Bioleaders Corporation's total assets have evolved over time, based on quarterly financial data. Explore Bioleaders Corporation (142760) investment intensity to see how much of total assets are deployed in long-term investments.
Bioleaders Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Bioleaders Corporation's total assets of ₩42.61 Billion consist of 62.3% current assets and 37.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 19.1% |
| Accounts Receivable | ₩3.33 Billion | 7.8% |
| Inventory | ₩2.40 Billion | 5.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.28 Billion | 3.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Bioleaders Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Bioleaders Corporation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioleaders Corporation's current assets represent 62.3% of total assets in 2025, a decrease from 82.8% in 2015.
- Cash Position: Cash and equivalents constituted 19.1% of total assets in 2025, down from 25.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 7.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 7.8% of total assets.
Bioleaders Corporation Competitors by Total Assets
Key competitors of Bioleaders Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Bioleaders Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 2.25 | 1.64 |
| Quick Ratio | 2.11 | 2.18 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩15.06 Billion | ₩25.74 Billion | ₩39.42 Billion |
Bioleaders Corporation - Advanced Valuation Insights
This section examines the relationship between Bioleaders Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -31.6% |
| Total Assets | ₩42.61 Billion |
| Market Capitalization | $16.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioleaders Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioleaders Corporation's assets decreased by 31.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioleaders Corporation (2015–2025)
The table below shows the annual total assets of Bioleaders Corporation from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩42.61 Billion ≈ $28.87 Million |
-31.56% |
| 2024-12-31 | ₩62.25 Billion ≈ $42.19 Million |
+26.85% |
| 2023-12-31 | ₩49.07 Billion ≈ $33.26 Million |
-66.94% |
| 2022-12-31 | ₩148.42 Billion ≈ $100.58 Million |
-21.41% |
| 2021-12-31 | ₩188.85 Billion ≈ $127.98 Million |
-0.97% |
| 2020-12-31 | ₩190.69 Billion ≈ $129.23 Million |
+28.75% |
| 2019-12-31 | ₩148.11 Billion ≈ $100.37 Million |
-3.38% |
| 2018-12-31 | ₩153.29 Billion ≈ $103.88 Million |
+307.95% |
| 2017-12-31 | ₩37.58 Billion ≈ $25.46 Million |
+73.86% |
| 2016-12-31 | ₩21.61 Billion ≈ $14.65 Million |
+126.55% |
| 2015-12-31 | ₩9.54 Billion ≈ $6.47 Million |
-- |
About Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more